Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder

被引:330
作者
Kato, M. [1 ,2 ]
Serretti, A. [1 ]
机构
[1] Univ Bologna, Inst Psychiat, I-40123 Bologna, Italy
[2] Kansai Med Univ, Dept Neuropsychiat, Osaka, Japan
关键词
depression; meta-analysis; polymorphism; treatment response; side effects; pharmacogenetics; SEROTONIN TRANSPORTER GENE; TRYPTOPHAN-HYDROXYLASE GENE; PROTEIN BETA-3 SUBUNIT; 5-HT2A RECEPTOR GENE; TERM TREATMENT RESPONSE; CONVERTING-ENZYME GENE; MONOAMINE-OXIDASE-A; FUNCTIONAL PROMOTER POLYMORPHISM; MESSENGER-RNA EXPRESSION; NEUROTROPHIC FACTOR GENE;
D O I
10.1038/mp.2008.116
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This systematic review summarizes pharmacogenetic studies on antidepressant response and side effects. Out of the 17 genes we reviewed, 8 genes were entered into the meta-analysis (SLC6A4, HTR1A, HTR2A, TPH1, gene encoding the beta-3 subunit, brain-derived neurotrophic factor (BDNF), HTR3A and HTR3B). TPH1 218C/C genotype (7 studies, 754 subjects) was significantly associated with a better response (odds ratio, OR = 1.62; P = 0.005) with no heterogeneity between ethnicities. A better response was also observed in subjects with the Met variant within the BDNF 66Val/Met polymorphism (4 studies, 490 subjects; OR = 1.63, P = 0.02). Variable number of tandem repeats polymorphism within intron 2 (STin2) 12/12 genotype showed a trend toward a better response in Asians (STin2: 5 studies, 686 subjects; OR = 3.89, P = 0.03). As for side effects, pooled ORs of serotonin transporter gene promoter polymorphism (5-HTTLPR) I (9 studies, 2642 subjects) and HTR2A - 1438G/G (7 studies, 801 subjects) were associated with a significant risk modulation (OR = 0.64, P = 0.0005) and (OR = 1.91, P = 0.0006), respectively. Interestingly, this significance became more robust when analyzed with side effect induced by selective serotonin reuptake inhibitors only (5-HTTLPR: P = 0.0001, HTR2A: P < 0.0001). No significant result could be observed for the other variants. These results were not corrected for multiple testing in each variant, phenotype and subcategory. This would have required a Bonferroni significance level of P < 0.0023. Although some heterogeneity was present across studies, our finding suggests that 5-HTTLPR, STin2, HTR1A, HTR2A, TPH1 and BDNF may modulate antidepressant response. Molecular Psychiatry (2010) 15, 473-500; doi:10.1038/mp.2008.116; published online 4 November 2008
引用
收藏
页码:473 / 500
页数:28
相关论文
共 185 条
[91]   Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders [J].
Liu, Zhongchun ;
Zhu, Fan ;
Wang, Gaohua ;
Xiao, Zheman ;
Tang, Jihua ;
Liu, Wanhong ;
Wang, Huiling ;
Liu, Hao ;
Wang, Xiaoping ;
Wu, Yingliang ;
Cao, Zhijian ;
Li, Wenxin .
NEUROSCIENCE LETTERS, 2007, 414 (02) :155-158
[92]   Meta-analyses of genetic studies on major depressive disorder [J].
Lopez-Leon, S. ;
Janssens, A. C. J. W. ;
Ladd, A. M. Gonzalez-Zuloeta ;
Del-Favero, J. ;
Claes, S. J. ;
Oostra, B. A. ;
van Duijn, C. M. .
MOLECULAR PSYCHIATRY, 2008, 13 (08) :772-785
[93]   A serotonin transporter gene intron 2 polymorphic region, correlated with affective disorders, has allele-dependent differential enhancer-like properties in the mouse embryo [J].
MacKenzie, A ;
Quinn, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (26) :15251-15255
[94]  
Männistö PT, 1999, PHARMACOL REV, V51, P593
[95]   Tolerability and adherence issues in antidepressant therapy [J].
Masand, PS .
CLINICAL THERAPEUTICS, 2003, 25 (08) :2289-2304
[96]   Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment [J].
McMahon, FJ ;
Buervenich, S ;
Charney, D ;
Lipsky, R ;
Rush, AJ ;
Wilson, AF ;
Sorant, AJM ;
Papanicolaou, GJ ;
Laje, G ;
Fava, M ;
Trivedi, MH ;
Wisniewski, SR ;
Manji, H .
AMERICAN JOURNAL OF HUMAN GENETICS, 2006, 78 (05) :804-814
[97]   Serotonin-2A-receptor and -transporter polymorphisms:: lack of association in patients with major depression [J].
Minov, C ;
Baghai, TC ;
Schüle, C ;
Zwanzger, P ;
Schwarz, MJ ;
Zill, P ;
Rupprecht, R ;
Bondy, B .
NEUROSCIENCE LETTERS, 2001, 303 (02) :119-122
[98]  
MIYAKE A, 1995, MOL PHARMACOL, V48, P407
[99]  
MONCRIEFF J, 2005, BMJ-BRIT MED J, V331, P551
[100]   Moclobemide response in depressed patients:: Association study with a functional polymorphism in the monoamine oxidase A promoter [J].
Müller, DJ ;
Schulze, TG ;
Macciardi, F ;
Ohlraun, S ;
Gross, MM ;
Scherk, H ;
Neidt, H ;
Syagailo, YV ;
Grässle, M ;
Nöthen, MM ;
Maier, W ;
Lesch, KP ;
Rietschel, M .
PHARMACOPSYCHIATRY, 2002, 35 (04) :157-158